CClinicalTrials.gg
CompletedNCT05795868Updated Apr 3, 2023

The Effect of Compression Stockings on the Complaints of Pregnant Women With Restless Leg Syndrome

An interventional study of Compression stocks and Knee socks in Restless Legs Syndrome, Pregnancy Related and Sleep Disorder, sponsored by TC Erciyes University. Completed at 2 sites in Turkey. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-03.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2022, registered Mar 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The aim of this project is to determine the effect of compression stockings on the complaints, well-being and sleep quality of pregnant women with restless legs syndrome (RLS). The research is a pretest-posttest randomized placebo-controlled experimental study. The study will be carried out with a total of 70 people, 35 in the compression stocking group and 35 in the placebo stocking group. Study data will be collected with RLS Diagnostic Criteria Questionnaire Form, Research Criteria Compliance Form, Personal Information Form, RLS Severity Rating Scale, Pittsburgh Sleep Quality Index (PUKI), WHO-5 and Implementation Satisfaction Form. Pregnant women in both groups will wear the stockings given for three weeks after the first interview.

Data analysis obtained in the research will be performed in TURCOSA statistical software (Turcosa Analytics Ltd Co, Turkey, www.turcosa.com.tr).In comparisons, a value of p \<0.05 will be considered statistically significant. In order to conduct the study, the necessary Academic Committee decision, Ethics Committee approval (December 08, 2021 and number 2021/781) and institutional permission were obtained. The individuals included in the study will be informed about the purpose of the research, their verbal consent will be obtained and the participant's informed consent form will be signed.

02

Conditions studied

  • Restless Legs Syndrome
  • Pregnancy Related
  • Sleep Disorder
03

In context

Sleep Wake Disorders

788 studies on the registry are indexed under Sleep Wake Disorders; 186 are open to participants now.

This study's enrollment of 70 is above the median of 62 across 548 interventional studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

TC Erciyes University is the lead sponsor of 341 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Least literate,
  2. Between the ages of 18 and 40,
  3. At 27 and above gestational week,
  4. Single pregnancy,
  5. Presence of RLS according to the RLS Diagnostic Criteria Questionnaire Form,
  6. Having a severity of 11 and above according to the RLS Severity Rating Scale,
  7. Using Iron, Vitamin D, Magnesium and Calcium,
  8. Pregnant women with a hemoglobin level of 11 g/dl and above,
  9. Pregnant women who can wear socks all day long, except for going to sleep, will be included in the study.

Exclusion criteria

Exclusion Criteria:

  1. Having a communication barrier,
  2. Having a risky pregnancy (risk of preterm labor, cervical insufficiency, preeclampsia, polyhydramnios, macrosomic baby, etc.),
  3. Having RLS before pregnancy,
  4. Having a chronic disease (Diabetes, hypertension, thyroid, cardiovascular disease, etc.),
  5. With maternal obesity (BMI>30)
  6. Having sleep apnea before pregnancy,
  7. Having any psychiatric disease and using antipsychotic and antidepressant drugs,
  8. Using heparin, antihistamine, antiemetic, calcium channel blocker, dextromethorphan and decongestant type drugs,
  9. Having a dermatological problem in the feet and legs,
  10. Pregnant women with varicose veins on their feet and legs will not be included in the study
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Compression stockings group

    Pregnant women in the compression stockings group will wear the socks given for 3 weeks.

    Device: Compression stocks

  • Placebo comparator
    Placebo sock group

    Pregnant women in the placebo socks group will wear the socks given for 3 weeks.

    Other: Knee socks

Interventions

  • DeviceCompression stocks

    Pregnant women in the compression stockings group will wear the socks given for 3 weeks.

  • OtherKnee socks

    Pregnant women in the Knee socks group will wear the socks given for 3 weeks.

06

What researchers measure

Primary outcomes

  1. RLS Severity Rating Scale

    The RLS Severity Rating Scale was developed in 2003 by the International Restless Legs Syndrome Study Group. The scale was applied in the selection of patients and in the weekly evaluation of RLS severity. The scale comprised ten questions; each question was scored between 0 and 4. Questions 1, 2, 4, 6, 7, and 8 were related to RLS symptoms, questions 5, 9, and 10 were related to the effect of the disease on the mental state and daily social activities of patients with RLS, and question 3 was about the diagnostic criteria of RLS. The overall score indicated the RLS severity. A minimum score of 0 and a maximum score of 40 could be obtained. A score between 1 and 10 corresponded to "mild," 11-20 "moderate," 21-30 "severe," and 31-40 "very severe" RLS.

    Time frame: Change from baseline score at the end of 21. days

Secondary outcomes

  1. Pittsburgh Sleep Quality Index

    The form consists of a total of 24 questions. Each question is scored between 0 and 3. Pittsburgh Sleep Quality Index score in the 0-21 range, with high scores indicating poor sleep quality. If the Pittsburgh Sleep Quality Index global score is greater than 5, it indicates that the sleep quality is significantly worse. The fact that the Pittsburgh Sleep Quality Index score is above 5 indicates that the person has serious trouble in at least two areas related to his sleep, or that he has mild or moderate difficulty in more than three areas.

    Time frame: Change from baseline score at the end of 21. days

Other outcomes

  1. World Health Organization-5 Index of Well-being (WHO-5)

    The WHO-5 questionnaire consists of 5 items containing positive statements about the participant's feelings in the last 2 weeks. Each item is evaluated on a 6-point Likert-type scale between 0-5; 0 points indicates no positive feelings in the last 2 weeks, 5 points indicates continuous positive feelings. The raw score is calculated by adding the numbers from the five answers. The total score that can be obtained from the scale varies between 0 and 25. 0 represents the worst possible quality of life and 25 the best possible quality of life, while a score below 13 indicates poor quality of life.

    Time frame: Change from baseline score at the end of 21. days

07

Study locations

2 sites
  • Özlem Kaplan
    Kayseri, 38280, Turkey
  • Erciyes University
    Kayseri, Turkey
08

References and documents

Individual participant data

Plan to share: No — Will be shared after the study ends.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05795868
Lead sponsor
TC Erciyes University
Collaborators
The Scientific and Technological Research Council of Turkey
Responsible party
Ozlem Kaplan (Reserch Asistant, TC Erciyes University) — Principal investigator
First posted
Apr 3, 2023
Start date
Apr 25, 2022
Primary completion
Apr 30, 2022
Completion
Mar 20, 2023
Last update
Apr 3, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion